NASDAQ:NXL Nexalin Technology Q3 2026 Earnings Results & Report $1.48 -0.01 (-0.67%) Closing price 11/13/2026 03:59 PM EasternExtended Trading$1.49 +0.01 (+0.61%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Nexalin Technology missed analyst earnings expectations but beat on revenue in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$3.43 versus the -$2.91 consensus estimate, while revenue of $78.30 thousand topped the $75 thousand estimate by $3.30 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 12, 2026TimeAfter Market ClosesConference Call7:00 AM ET Nexalin Technology EPS ResultsActual EPS-$3.43Consensus EPS -$2.91Beat/MissMissed by -$0.52One Year Ago EPSN/AEPS Beat Rate2 of last 7 quartersNexalin Technology Revenue ResultsActual Revenue$78.30 thousandExpected Revenue$75 thousandBeat/MissBeat by +$3.30 thousandYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Nexalin Technology Q3 2026 Earnings FAQ Did Nexalin Technology beat earnings estimates for Q3 2026? Nexalin Technology (NASDAQ:NXL) reported earnings of -$3.43 per share for Q3 2026, missing the consensus estimate of -$2.91. The report was announced on Thursday, November 12, 2026. What was Nexalin Technology's revenue for Q3 2026? Nexalin Technology reported revenue of $78.30 thousand for Q3 2026, against a consensus estimate of $75 thousand. Nexalin Technology Earnings HeadlinesNexalin Technology, Inc. (NASDAQ:NXL) Stock Short Interest Jumps 180.7%November 13 at 4:03 AM | americanbankingnews.comNexalin Technology (NXL) Set to Release Quarterly Earnings on FridayNovember 6, 2026 | americanbankingnews.comThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.November 14 at 1:00 AM | Weiss Ratings (Ad)Nexalin’s HALO Clarity™ Insomnia Trial Moves Toward Launch: What Investors Need to KnowOctober 30, 2026 | tipranks.comNXL - Nexalin Technology, Inc.October 28, 2026 | seekingalpha.comNexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS™ Significantly Improves Sleep Quality in Patients with Mild Alzheimer's DiseaseOctober 27, 2026 | globenewswire.comSee More Nexalin Technology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nexalin Technology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nexalin Technology and other key companies, straight to your email. Email Address About Nexalin TechnologyNexalin Technology (NASDAQ:NXL) (NASDAQ:NXL) is a medical technology company focused on developing and commercializing noninvasive neurostimulation devices for mental health and neurological applications. Its technology is designed to deliver low-intensity electrical stimulation to the brain with the goal of influencing neural activity associated with conditions such as depression, anxiety, insomnia, post-traumatic stress disorder and substance-use disorders. The company’s product portfolio includes the Gen-2 and Gen-3 neurostimulation systems. These devices use Nexalin’s proprietary waveform and transcranial electrical stimulation technology. The Gen-2 system has received regulatory clearance for certain uses, while the company continues to develop and evaluate newer-generation systems and additional clinical applications. Nexalin was founded in 2003 and is headquartered in Houston, Texas. The company serves healthcare providers and other potential institutional customers and has pursued commercial and distribution opportunities in international markets. Its products are intended to provide a noninvasive alternative or complement to conventional approaches for addressing symptoms related to mental health and brain-function disorders.View Nexalin Technology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?YETI Beat on Earnings, But Its Sales Tell a Different StoryCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
